Squarer Ron
SEC insider (Form 3/4/5 filer). CIK 0001454001. Director at Nuvalent, Inc. (NUVL) and 2 other issuers. 9 reported Form 4/5 transactions since Sep 2024; latest on Jul 15, 2026. Located in CAMBRIDGE, MA.
Companies Squarer Ron has filed insider reports for
- Nuvalent, Inc. (NUVL): Director
- ADC Therapeutics SA (ADCT): Director
- Travere Therapeutics, Inc. (TVTX): Director
Squarer Ron
CIK: 0001454001
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)6 (66.7%)
Compensation grants
Other (G, F, J, C, D, …)3 (33.3%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jul 15, 2026NUVL
Nuvalent, Inc.
DispositionDirect6.3K shares- - Jun 16, 2026NUVL
Nuvalent, Inc.
AwardDirect3.4K shares- - Jun 3, 2026ADCT
ADC Therapeutics SA
Tax PaymentDirect15.2K shares at avg. $3.08$47K - Jun 1, 2026ADCT
ADC Therapeutics SA
AwardDirect45K shares- - May 19, 2026TVTX
Travere Therapeutics, Inc.
AwardDirect4K shares- - Dec 10, 2025NUVL
Nuvalent, Inc.
AwardDirect2.8K shares- - Jun 13, 2025ADCT
ADC Therapeutics SA
Tax PaymentDirect15.2K shares at avg. $3.58$54K - Jun 3, 2025ADCT
ADC Therapeutics SA
AwardDirect40K shares- - May 15, 2025TVTX
Travere Therapeutics, Inc.
AwardDirect6.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 15, 2026 |  NUVL Nuvalent, Inc. | Disposition | 6,281 | - | $0 | Direct |
| Jun 16, 2026 | NUVL Nuvalent, Inc. | Award | 3,444 | - | $0 | Direct |
| Jun 3, 2026 |  ADCT ADC Therapeutics SA | Tax Payment | 15,196 | $3.08 | $46,804 | Direct |
| Jun 1, 2026 | ADCT ADC Therapeutics SA | Award | 45,000 | - | $0 | Direct |
| May 19, 2026 |  TVTX Travere Therapeutics, Inc. | Award | 4,000 | - | $0 | Direct |
| Dec 10, 2025 | NUVL Nuvalent, Inc. | Award | 2,837 | - | - | Direct |
| Jun 13, 2025 | ADCT ADC Therapeutics SA | Tax Payment | 15,184 | $3.58 | $54,359 | Direct |
| Jun 3, 2025 | ADCT ADC Therapeutics SA | Award | 40,000 | - | - | Direct |
| May 15, 2025 | TVTX Travere Therapeutics, Inc. | Award | 6,500 | - | - | Direct |
1-9 of 9 transactions